Simpson Thacher partners offer IPO tips for private companies, noting that having an independent board and the correct ...

Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of 2025.

The revenue from operations jumped 43% YoY to ₹291 crore in Q2 FY25, compared to ₹203 crore in the same quarter of the previous year.

HBM Healthcare Investments AG / Key word (s): Quarter Results HBM Healthcare Investments reports a compelling 15 percent increase in NAV in the 2024 calendar year 03-Jan-2025 / 17:48 CET/CEST Release ...

The IPO is entirely an OFS, the company will not receive any funds from the issue and the proceeds will go to the selling ...

Anthem Biosciences, a CRDMO specializing in drug discovery, development and manufacturing, has filed draft papers with Sebi ...

Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, ...

Anthem, whose services include early-stage drug discovery and drug efficacy testing, said private equity firm True North and drugmaker DavosPharma are among investors who will sell shares in the IPO.

The successful debuts are expected to boost the IPO market, with eight new issuances ... retailer Vishal Mega Mart and pharma firm Sai Life Sciences gained around 40 per cent each.

Three companies - Vishal Mega Mart, Sai Life Sciences and One Mobikwik - that together raised Rs 11,615 crore last week, ...

Successful IPO of HBM portfolio company Sai Life Sciences on the Indian stock exchanges NSE and BSE increases NAV per HBM share by 3.2 percent 18-Dec-2024 / 17:46 CET/CEST Release of an ad hoc ...